Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
- Associated Therapies
- -
Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT02306889
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 362
- Registration Number
- NCT02262143
- Locations
- 🇰🇷
Ildong Pharm., Seoul, Korea, Republic of
Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Institut Investigacio Sanitaria Pere Virgili
- Target Recruit Count
- 30
- Registration Number
- NCT02153879
- Locations
- 🇪🇸
Hospital Universitari Sant Joan, Reus, Tarragona, Spain
CKD-337 Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT02066207
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Koval' O., MD
- Target Recruit Count
- 60
- Registration Number
- NCT02015988
- Locations
- 🇺🇦
State Institution "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dnipropetrovsk, Ukraine
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 6
- Registration Number
- NCT01965834
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Lipid Biomarkers for Diabetic Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 70
- Registration Number
- NCT01752842
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT01723735
- Locations
- 🇫🇷
Investigational Site Number 250001, Rennes, France
🇫🇷Investigational Site Number 250002, Rueil Malmaison, France
Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT01666041
- Locations
- 🇰🇷
Gil Medical Center, Incheon, Korea, Republic of
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01594983
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.